A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin on functional outcomes in anemic, critically ill, trauma subjects: The Long Term Trauma Outcomes Study

Fred A. Luchette, Michael D. Pasquale, Timothy Fabian, Wayne K. Langholff, Marsha Wolfson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Achieving a higher hemoglobin (Hb) level might allow the anemic, critically ill, trauma patient to have an improved outcome during rehabilitation therapy. Methods: Patients with major blunt trauma orthopedic injuries were administered epoetin alfa or placebo weekly both in hospital and for up to 12 weeks after discharge or until the Hb level was >12.0 g/dL, whichever occurred first. The 36-question Short Form Health Assessment questionnaire (SF-36) was used to evaluate physical function (PF) outcomes at baseline, at hospital discharge, and at several time points posthospital discharge. Results: One hundred ninety-two patients were enrolled (epoetin alfa [n = 97], placebo [n = 95]). Hb increased from baseline to hospital discharge in both groups (epoetin alfa: 1.2 g/dL vs placebo: 0.9 g/dL), and transfusion requirements were similar between groups. Both groups showed improvements in SF-36 PF; there were no significant differences in the average of all posthospital discharge scores (epoetin alfa: 27.3 vs placebo 30.9; P = 0.38). Thromboembolic events were similar between groups. Conclusions: No differences were observed in physical function outcomes or safety in anemic, critically ill, trauma patients treated with epoetin alfa compared with placebo.

Original languageEnglish (US)
Pages (from-to)508-516
Number of pages9
JournalAmerican Journal of Surgery
Volume203
Issue number4
DOIs
StatePublished - Apr 1 2012

Fingerprint

Epoetin Alfa
Erythropoietin
Critical Illness
Placebos
Outcome Assessment (Health Care)
Wounds and Injuries
Hemoglobins
Orthopedics
Safety

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin on functional outcomes in anemic, critically ill, trauma subjects : The Long Term Trauma Outcomes Study. / Luchette, Fred A.; Pasquale, Michael D.; Fabian, Timothy; Langholff, Wayne K.; Wolfson, Marsha.

In: American Journal of Surgery, Vol. 203, No. 4, 01.04.2012, p. 508-516.

Research output: Contribution to journalArticle

@article{73126cb99bed4a4d9c47e3a541de9d36,
title = "A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin on functional outcomes in anemic, critically ill, trauma subjects: The Long Term Trauma Outcomes Study",
abstract = "Background: Achieving a higher hemoglobin (Hb) level might allow the anemic, critically ill, trauma patient to have an improved outcome during rehabilitation therapy. Methods: Patients with major blunt trauma orthopedic injuries were administered epoetin alfa or placebo weekly both in hospital and for up to 12 weeks after discharge or until the Hb level was >12.0 g/dL, whichever occurred first. The 36-question Short Form Health Assessment questionnaire (SF-36) was used to evaluate physical function (PF) outcomes at baseline, at hospital discharge, and at several time points posthospital discharge. Results: One hundred ninety-two patients were enrolled (epoetin alfa [n = 97], placebo [n = 95]). Hb increased from baseline to hospital discharge in both groups (epoetin alfa: 1.2 g/dL vs placebo: 0.9 g/dL), and transfusion requirements were similar between groups. Both groups showed improvements in SF-36 PF; there were no significant differences in the average of all posthospital discharge scores (epoetin alfa: 27.3 vs placebo 30.9; P = 0.38). Thromboembolic events were similar between groups. Conclusions: No differences were observed in physical function outcomes or safety in anemic, critically ill, trauma patients treated with epoetin alfa compared with placebo.",
author = "Luchette, {Fred A.} and Pasquale, {Michael D.} and Timothy Fabian and Langholff, {Wayne K.} and Marsha Wolfson",
year = "2012",
month = "4",
day = "1",
doi = "10.1016/j.amjsurg.2011.08.006",
language = "English (US)",
volume = "203",
pages = "508--516",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin on functional outcomes in anemic, critically ill, trauma subjects

T2 - The Long Term Trauma Outcomes Study

AU - Luchette, Fred A.

AU - Pasquale, Michael D.

AU - Fabian, Timothy

AU - Langholff, Wayne K.

AU - Wolfson, Marsha

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Background: Achieving a higher hemoglobin (Hb) level might allow the anemic, critically ill, trauma patient to have an improved outcome during rehabilitation therapy. Methods: Patients with major blunt trauma orthopedic injuries were administered epoetin alfa or placebo weekly both in hospital and for up to 12 weeks after discharge or until the Hb level was >12.0 g/dL, whichever occurred first. The 36-question Short Form Health Assessment questionnaire (SF-36) was used to evaluate physical function (PF) outcomes at baseline, at hospital discharge, and at several time points posthospital discharge. Results: One hundred ninety-two patients were enrolled (epoetin alfa [n = 97], placebo [n = 95]). Hb increased from baseline to hospital discharge in both groups (epoetin alfa: 1.2 g/dL vs placebo: 0.9 g/dL), and transfusion requirements were similar between groups. Both groups showed improvements in SF-36 PF; there were no significant differences in the average of all posthospital discharge scores (epoetin alfa: 27.3 vs placebo 30.9; P = 0.38). Thromboembolic events were similar between groups. Conclusions: No differences were observed in physical function outcomes or safety in anemic, critically ill, trauma patients treated with epoetin alfa compared with placebo.

AB - Background: Achieving a higher hemoglobin (Hb) level might allow the anemic, critically ill, trauma patient to have an improved outcome during rehabilitation therapy. Methods: Patients with major blunt trauma orthopedic injuries were administered epoetin alfa or placebo weekly both in hospital and for up to 12 weeks after discharge or until the Hb level was >12.0 g/dL, whichever occurred first. The 36-question Short Form Health Assessment questionnaire (SF-36) was used to evaluate physical function (PF) outcomes at baseline, at hospital discharge, and at several time points posthospital discharge. Results: One hundred ninety-two patients were enrolled (epoetin alfa [n = 97], placebo [n = 95]). Hb increased from baseline to hospital discharge in both groups (epoetin alfa: 1.2 g/dL vs placebo: 0.9 g/dL), and transfusion requirements were similar between groups. Both groups showed improvements in SF-36 PF; there were no significant differences in the average of all posthospital discharge scores (epoetin alfa: 27.3 vs placebo 30.9; P = 0.38). Thromboembolic events were similar between groups. Conclusions: No differences were observed in physical function outcomes or safety in anemic, critically ill, trauma patients treated with epoetin alfa compared with placebo.

UR - http://www.scopus.com/inward/record.url?scp=84859107597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859107597&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2011.08.006

DO - 10.1016/j.amjsurg.2011.08.006

M3 - Article

C2 - 22177550

AN - SCOPUS:84859107597

VL - 203

SP - 508

EP - 516

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 4

ER -